ERBB2 and neoplasm: In trastuzumab-resistant models lacking p95-HER2 expression, prolonged treatment with HSP90 inhibitors in vivo results in the sustained loss of both HER2 and p95-HER2, the inhibition of AKT activation, the induction of apoptosis, and the complete suppression of tumor growth [68].